0001645113-26-000050
SEC filingNovoCure held its annual general meeting, electing directors and approving shareholder proposals including auditor ratification and executive compensation.
The 8-K reports the results of NovoCure's 2026 annual general meeting. All 11 director nominees were elected with strong support, though some candidates (e.g., Kinyip Gabriel Leung) received slightly more against votes. The ratification of auditors was routine, with over 97% of votes cast in favor. The advisory vote on executive compensation passed with about 91% of votes cast in favor, indicating shareholder satisfaction with pay practices. Notably, the amended omnibus incentive plan passed by a very slim margin (41,680,622 For vs 41,161,139 Against), reflecting potential shareholder concerns about dilution or structure. The plan allows for equity grants to attract and retain talent. Overall, the meeting outcomes support continued governance stability.